AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 101 min read$ISRG

LOEB GARY sold $170K of ISRG

LOEB GARY (EVP & Chief Legal and Complian) sold 400 shares of INTUITIVE SURGICAL INC (ISRG) at $424.14 ($0.17M total) on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LOEB GARY
Published Jun 10, 2026, 9:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ISRG
Neutral
medium confidence
Mentioned
$ISRG
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The disclosure adds a fresh datapoint on insider activity but does not include any operational, financial, or regulatory change.

02

Market read

A modest, pre-arranged insider sale is unlikely to drive a sustained repricing without accompanying company-specific catalysts.

03

What to watch

Traders may over-weight small insider sales; the key is whether there are repeated sales patterns or concurrent operational/regulatory news (not present here).

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-10 (transaction dated 2026-06-10)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG).

Company-level read

Ticker impact

$ISRGNeutralMedium confidence
Context

Intuitive Surgical disclosed an open-market sale by EVP & Chief Legal and Compliance Officer Gary Loeb: 400 shares sold at $424.14 on 2026-06-10 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly states a pre-arranged Rule 10b5-1 plan; the disclosed size ($169.7k) is small relative to typical ISRG market context, so it’s unlikely to change earnings or risk materially.

Market effects

Sector

No clear read-across to medical device sector fundamentals; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity/tax planning rather than bearish expectations.

Key entities

  • issuer
    ISRG

    Intuitive Surgical, Inc., the subject of the Form 4 insider transaction.

  • insider
    Gary Loeb

    EVP & Chief Legal and Compliance Officer who sold 400 shares on 2026-06-10 under a Rule 10b5-1 plan.

Read at source← All news

Related articles

JUL 28
$ISRGMed

UBS starts medtech coverage, favors Intuitive Surgical and Enovis By Investing.com

UBS initiated coverage of four U.S. medtech firms. It assigned Buy ratings to Intuitive Surgical (ISRG) with a $500 price target and Enovis (ENOV) with a $51 target, citing growth drivers and improving fundamentals. UBS gave Inspire Medical Systems (INSP) a Sell rating with a $39 target and Integra LifeSciences (IART) a Neutral rating with a $19 target, citing competition, reimbursement and limited catalysts.

investing.com4 min
JUL 27
$UNHMed

UnitedHealth Group Incorporated (UNH) and Intuitive Surgical, Inc. (ISRG) Just Showed Why Beating Estimates Isn’t Enough

UnitedHealth (UNH) and Intuitive Surgical (ISRG) both beat July earnings estimates. UNH reported adjusted EPS of $6.38 vs $4.90 expected, revenue of $112B, and raised full-year profit guidance to $19.50-$20. ISRG reported $2.89B revenue and $2.80 EPS vs $2.50 expected, but shares fell after guidance implied slower procedure growth near the middle of its range.

yahoo.com6 min
JUL 26
$ISRGMedAI 8/10

The $100 Billion Surgery Giant That Wall Street Suddenly Doesn't Trust

Intuitive Surgical reported Q2 adjusted EPS of $2.80 vs $2.50 expected and revenue of $2.89B vs $2.82B, with 468 new da Vinci systems installed and an installed base of 11,710. Shares fell over 9% after-hours and trade near the 52-week low. Guidance for 2026 was confirmed but not raised, while analysts cited ACA subsidy changes, GLP-1 impacts, and tariffs.

ad-hoc-news.de6 min
JUL 22
$JNJMedAI 8/10

Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today

Intuitive Surgical (ISRG) shares fell after Johnson & Johnson (JNJ) received U.S. FDA marketing authorization for its Ottava robotic surgical platform. The article says JNJ plans an immediate U.S. commercial rollout and faster launches in Western Europe and Japan, positioning Ottava as a competitive alternative to ISRG’s da Vinci systems. It cites ISRG down about 35% YTD and options data implying further near-term downside.

barchart.com5 min